MO1-2 Safety profile of LIGHT-NING 3rd interim analysis: 1L nivolumab + ipilimumab +/− chemotherapy for metastatic NSCLC.

Authors :: Azuma, K.
Imai, H.
Yamaguchi, T.
Kijima, T.
Kishi, K.
Fujita, K.
Saito, H.
Shiraishi, Y.
Tanizaki, J.
Takashima, Y.
Tambo, Y.
Watanabe, S.
Hataji, O.
Toi, Y.
Fukuhara, T.
Ohsugi, T.
Kuroda, H.
Ohe, Y.
Horinouchi, H.
Source :: Annals of Oncology. Oct2024:Supplement 3, Vol. 35, pS1328-S1328. 1p.
Publication Year :: 2024

Subjects :: *NIVOLUMAB
*IPILIMUMAB
*NON-small-cell lung carcinoma
*CANCER chemotherapy
*METASTASIS

Full Text Access

Tools